Wall Street analysts expect Integer Holdings Corp (NYSE:ITGR) to post $320.50 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Integer’s earnings. Integer posted sales of $303.03 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5.8%. The firm is expected to announce its next earnings report on Thursday, February 20th.
On average, analysts expect that Integer will report full year sales of $1.25 billion for the current year. For the next financial year, analysts expect that the company will report sales of $1.29 billion, with estimates ranging from $1.29 billion to $1.30 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Integer.
Integer (NYSE:ITGR) last posted its earnings results on Thursday, October 31st. The medical equipment provider reported $1.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.14. The business had revenue of $303.59 million during the quarter, compared to analyst estimates of $313.78 million. Integer had a return on equity of 13.47% and a net margin of 8.99%. The company’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.06 EPS.
ITGR stock traded down $0.92 during mid-day trading on Thursday, reaching $78.85. 121,370 shares of the company traded hands, compared to its average volume of 168,071. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.40 and a quick ratio of 1.35. The company has a market capitalization of $2.61 billion, a P/E ratio of 20.75 and a beta of 1.01. Integer has a 52-week low of $67.72 and a 52-week high of $92.61. The company has a fifty day moving average price of $76.01 and a 200-day moving average price of $77.45.
In related news, Director Pamela G. Bailey sold 7,446 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $76.75, for a total value of $571,480.50. Following the completion of the sale, the director now owns 56,990 shares in the company, valued at approximately $4,373,982.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter H. Soderberg sold 1,766 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $79.24, for a total value of $139,937.84. Company insiders own 2.24% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. State of Tennessee Treasury Department grew its stake in Integer by 30.6% in the third quarter. State of Tennessee Treasury Department now owns 24,907 shares of the medical equipment provider’s stock worth $1,882,000 after purchasing an additional 5,834 shares during the period. Gabelli Funds LLC increased its position in Integer by 42.3% in the third quarter. Gabelli Funds LLC now owns 74,000 shares of the medical equipment provider’s stock worth $5,591,000 after buying an additional 22,000 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Integer by 12.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 42,712 shares of the medical equipment provider’s stock worth $3,227,000 after buying an additional 4,764 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Integer in the third quarter worth about $907,000. Finally, SG Americas Securities LLC increased its position in Integer by 68.2% in the second quarter. SG Americas Securities LLC now owns 3,844 shares of the medical equipment provider’s stock worth $323,000 after buying an additional 1,559 shares in the last quarter. 98.09% of the stock is currently owned by institutional investors.
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
See Also: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.